Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Stadsomvaart 11, 3500 Hasselt, Belgium.
EUSTRATEGY Association, Forli' (FC), Italy.
Eur Heart J. 2017 Apr 7;38(14):1069-1080. doi: 10.1093/eurheartj/ehx048.
To assess whether radial compared with femoral access is associated with consistent outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
In the Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX) programme patients were randomized to radial or femoral access, stratified by STEMI (2001 radial, 2009 femoral) and NSTE-ACS (2196 radial, 2198 femoral). The 30-day co-primary outcomes were major adverse cardiovascular events (MACE), defined as death, myocardial infarction, or stroke, and net adverse clinical events (NACE), defined as MACE or major bleeding In the overall study population, radial access reduced the NACE but not MACE endpoint at the prespecified 0.025 alpha. MACE occurred in 121 (6.1%) STEMI patients with radial access vs. 126 (6.3%) patients with femoral access [rate ratio (RR) = 0.96, 95% CI = 0.75-1.24; P = 0.76] and in 248 (11.3%) NSTE-ACS patients with radial access vs. 303 (13.9%) with femoral access (RR = 0.80, 95% CI = 0.67-0.96; P = 0.016) (Pint = 0.25). NACE occurred in 142 (7.2%) STEMI patients with radial access and in 165 (8.3%) patients with femoral access (RR = 0.86, 95% CI = 0.68-1.08; P = 0.18) and in 268 (12.2%) NSTE-ACS patients with radial access compared with 321 (14.7%) with femoral access (RR = 0.82, 95% CI = 0.69-0.97; P = 0.023) (Pint = 0.76). All-cause mortality and access site-actionable bleeding favoured radial access irrespective of ACS type (Pint = 0.11 and Pint = 0.36, respectively).
Radial as compared with femoral access provided consistent benefit across the whole spectrum of patients with ACS, without evidence that type of presenting syndrome affected the results of the random access allocation.
评估与股动脉入路相比,桡动脉入路是否与 ST 段抬高型心肌梗死(STEMI)和非 ST 段抬高型急性冠脉综合征(NSTE-ACS)患者的一致结果相关。
在 Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX) 项目中,患者被随机分配至桡动脉或股动脉入路,按 STEMI(2001 例桡动脉,2009 例股动脉)和 NSTE-ACS(2196 例桡动脉,2198 例股动脉)分层。30 天的主要复合终点为主要不良心血管事件(MACE),定义为死亡、心肌梗死或卒中,以及净不良临床事件(NACE),定义为 MACE 或主要出血。在整个研究人群中,桡动脉入路降低了预先设定的 0.025 α 水平的 NACE,但未降低 MACE 终点。在桡动脉入路的 121 例(6.1%)STEMI 患者中发生 MACE,而在股动脉入路的 126 例(6.3%)患者中发生 MACE[比值比(RR)=0.96,95%CI=0.75-1.24;P=0.76],在桡动脉入路的 248 例(11.3%)NSTE-ACS 患者中发生 MACE,而在股动脉入路的 303 例(13.9%)患者中发生 MACE(RR=0.80,95%CI=0.67-0.96;P=0.016)(Pint=0.25)。在桡动脉入路的 142 例(7.2%)STEMI 患者和股动脉入路的 165 例(8.3%)患者中发生 NACE(RR=0.86,95%CI=0.68-1.08;P=0.18),在桡动脉入路的 268 例(12.2%)NSTE-ACS 患者和股动脉入路的 321 例(14.7%)患者中发生 NACE(RR=0.82,95%CI=0.69-0.97;P=0.023)(Pint=0.76)。无论 ACS 类型如何,桡动脉入路的全因死亡率和入路部位的操作相关出血均优于股动脉入路(Pint=0.11 和 Pint=0.36)。
与股动脉入路相比,桡动脉入路在 ACS 患者整个谱中提供了一致的益处,且无证据表明首发综合征类型影响随机入路分配的结果。